Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias
Maisa Yoshimoto(University of Alberta), Jeremy A. Squire(Universidade de São Paulo), Andrew Evans(University of Dundee), Paulo Nuin(Queen's University), Jane Bayani(Ontario Institute for Cancer Research), Anthony M. Joshua(St Vincent's Hospital Sydney), Maria Zieleńska(University of Toronto), Jean‐Claude Cutz(BC Cancer Agency)
Cited by 181
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
|JAMA|2016|1.1k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869